InterMune Wins Amid More Takeover Rumors

InterMune was the big winner in biotech today, up around 10% on rumors of a buyout. However, in this video from Friday's Market Checkup, Motley Fool health-care analyst David Williamson says that these rumors are as of yet completely unsubstantiated, and should not constitute an investing thesis.

He does discuss, however, why the company would make an attractive acquisition. Its first-in-class idiopathic pulmonary fibrosis drug Esbriet recently passed a new phase 3 trial, and is up again for FDA approval; the drug was approved in Europe in 2011. Esbriet makes up the entirety of InterMune's value, which makes it a very pure play, and a nice addition to just about any company's portfolio. David makes a prediction for who may buy the company down the road, discusses how big the upside could be for the drug, and cautions investors regarding how the downside could look, as well.

Want more predictable growth?
They said it couldn't be done. But David Gardner has proved them wrong, time, and time, and time again, with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

The article InterMune Wins Amid More Takeover Rumors originally appeared on

David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story